China Requires One Divestiture for Pfizer-Wyeth Merger
publication date: Sep 30, 2009
The Anti-Monopoly Bureau of China’s Ministry of Commerce (MOFCOM) has given its okay to the merger between Pfizer and Wyeth. However, MOFCOM will require that Pfizer divest its swine mycoplasmal pneumonia vaccine business. Pfizer has been negotiating with the Anti-Monopoly Bureau on the ruling, implying that it will not be surprised by the ruling, even if it may not agree. More details...
Stock Symbols: (NYSE: PFE) (NYSE: WYE)
Sorry... this feature or article is only available to subscribers.